VERTEX PHARMACEUTICALS INC / MA Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent of -$11.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax, parent for the quarter ending 2026-06-30 was -$11.20M, a 120.70% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax, parent for the quarter ending 2026-03-31 was -$23.90M, a 193.36% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax, parent for the quarter ending 2025-12-31 was -$14.30M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax, parent for the quarter ending 2025-09-30 was -$9.40M, a 154.34% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax, parent for fiscal 2025 was $56.00M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax, parent for fiscal 2024 was -$38.20M, a 372.86% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax, parent for fiscal 2023 was $14.00M, a 1300.00% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax, parent for fiscal 2022 was $1.00M.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.20M 10-Q · filed 2026-08-04 | -$35.10M 10-Q · filed 2026-08-04 | -$49.40M derived: sum of 3 quarters · filed 2026-08-04 | -$58.80M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$23.90M 10-Q · filed 2026-05-05 | -$38.20M derived: sum of 2 quarters · filed 2026-05-05 | -$47.60M derived: sum of 3 quarters · filed 2026-05-05 | $6.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$14.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$23.70M derived: sum of 2 quarters · filed 2026-02-13 | $30.40M derived: sum of 3 quarters · filed 2026-08-04 | $56.00M 10-K · filed 2026-02-13 |
| 2025-09-30 | -$9.40M 10-Q · filed 2025-11-04 | $44.70M derived: sum of 2 quarters · filed 2026-08-04 | $70.30M 10-Q · filed 2025-11-04 | $30.30M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $54.10M 10-Q · filed 2026-08-04 | $79.70M 10-Q · filed 2026-08-04 | $39.70M derived: sum of 3 quarters · filed 2026-08-04 | $57.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $25.60M 10-Q · filed 2026-05-05 | -$14.40M derived: sum of 2 quarters · filed 2026-05-05 | $2.90M derived: sum of 3 quarters · filed 2026-05-05 | -$300.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$22.70M derived: sum of 2 quarters · filed 2026-02-13 | -$25.90M derived: sum of 3 quarters · filed 2026-02-13 | -$38.20M 10-K · filed 2026-02-13 |
| 2024-09-30 | $17.30M 10-Q · filed 2025-11-04 | $14.10M derived: sum of 2 quarters · filed 2025-11-04 | $1.80M 10-Q · filed 2025-11-04 | $17.40M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | -$3.20M 10-Q · filed 2025-08-05 | -$15.50M 10-Q · filed 2025-08-05 | $100.00K derived: sum of 3 quarters · filed 2026-02-13 | -$13.10M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | -$12.30M 10-Q · filed 2025-05-06 | $3.30M derived: sum of 2 quarters · filed 2026-02-13 | -$9.90M derived: sum of 3 quarters · filed 2026-02-13 | -$5.70M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $15.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $2.40M derived: sum of 2 quarters · filed 2026-02-13 | $6.60M derived: sum of 3 quarters · filed 2026-02-13 | $14.00M 10-K · filed 2026-02-13 |
| 2023-09-30 | -$13.20M 10-Q · filed 2024-11-05 | -$9.00M derived: sum of 2 quarters · filed 2024-11-05 | -$1.60M 10-Q · filed 2024-11-05 | $33.70M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $4.20M 10-Q · filed 2024-08-02 | $11.60M 10-Q · filed 2024-08-02 | $46.90M derived: sum of 3 quarters · filed 2025-02-13 | $30.90M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $7.40M 10-Q · filed 2024-05-07 | $42.70M derived: sum of 2 quarters · filed 2025-02-13 | $26.70M derived: sum of 3 quarters · filed 2025-02-13 | $10.60M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $35.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $19.30M derived: sum of 2 quarters · filed 2025-02-13 | $3.20M derived: sum of 3 quarters · filed 2025-02-13 | $1.00M 10-K · filed 2025-02-13 |
| 2022-09-30 | -$16.00M 10-Q · filed 2023-11-07 | -$32.10M derived: sum of 2 quarters · filed 2023-11-07 | -$34.30M 10-Q · filed 2023-11-07 | -$34.90M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$16.10M 10-Q · filed 2023-08-02 | -$18.30M 10-Q · filed 2023-08-02 | -$18.90M derived: sum of 3 quarters · filed 2024-02-15 | -$28.50M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$2.20M 10-Q · filed 2023-05-02 | -$2.80M derived: sum of 2 quarters · filed 2024-02-15 | -$12.40M derived: sum of 3 quarters · filed 2024-02-15 | -$14.70M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$10.20M derived: sum of 2 quarters · filed 2024-02-15 | -$12.50M derived: sum of 3 quarters · filed 2024-02-15 | -$21.80M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$9.60M 10-Q · filed 2022-10-28 | -$11.90M derived: sum of 2 quarters · filed 2022-10-28 | -$21.20M 10-Q · filed 2022-10-28 | -$14.20M derived: sum of 4 quarters · filed 2023-02-10 |
| 2021-06-30 | -$2.30M 10-Q · filed 2022-08-05 | -$11.60M 10-Q · filed 2022-08-05 | -$4.60M derived: sum of 3 quarters · filed 2023-02-10 | $3.00M derived: sum of 4 quarters · filed 2023-02-10 |
| 2021-03-31 | -$9.30M 10-Q · filed 2022-05-06 | -$2.30M derived: sum of 2 quarters · filed 2023-02-10 | $5.30M derived: sum of 3 quarters · filed 2023-02-10 | $10.00M derived: sum of 4 quarters · filed 2023-02-10 |
| 2020-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $14.60M derived: sum of 2 quarters · filed 2023-02-10 | $19.30M derived: sum of 3 quarters · filed 2023-02-10 | $14.30M 10-K · filed 2023-02-10 |
| 2020-09-30 | $7.60M 10-Q · filed 2021-11-03 | $12.30M derived: sum of 2 quarters · filed 2021-11-03 | $7.30M 10-Q · filed 2021-11-03 | $8.80M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-06-30 | $4.70M 10-Q · filed 2021-07-30 | -$300.00K 10-Q · filed 2021-07-30 | $1.20M derived: sum of 3 quarters · filed 2022-02-09 | $3.40M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-03-31 | -$5.00M 10-Q · filed 2021-04-30 | -$3.50M derived: sum of 2 quarters · filed 2022-02-09 | -$1.30M derived: sum of 3 quarters · filed 2022-02-09 | $500.00K derived: sum of 4 quarters · filed 2022-02-09 |
| 2019-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $3.70M derived: sum of 2 quarters · filed 2022-02-09 | $5.50M derived: sum of 3 quarters · filed 2022-02-09 | $7.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $2.20M 10-Q · filed 2020-10-30 | $4.00M derived: sum of 2 quarters · filed 2020-10-30 | $5.50M 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $1.80M 10-Q · filed 2020-07-31 | $3.30M 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | $1.50M 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |